The FDA has approved the cobas Zika test, the first test for screening Zika virus in blood donations. It is a qualitative nucleic acid test for the detection of Zika virus RNA in individual plasma specimens obtained from volunteer donors of whole blood and blood components, and from living organ donors.
The test’s clinical specificity was evaluated by testing individual samples from blood donations at 5 external laboratory sites, resulting in clinical specificity of >99%.
The cobas Zika test is intended for use by blood collection establishments to detect Zika virus in blood donations, not for individual diagnosis of Zika virus infection. It is intended for use on the fully automated cobas 6800 and cobas 8800 systems, manufactured by Roche Molecular Systems, Inc.
US Food and Drug Administration. FDA approves first test for screening Zika virus in blood donations. FDA Web site. October 5, 2017. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm579313.htm. Accessed October 9, 2017.
This Week's Must Reads
Must Reads in FDA Actions
FDA Approves Firvanq for C.diff-associated Diarrhea, CutisPharma news release; 2018 Jan 29
FDA Expands Indication for Influenza Vaccine, GSK news release; 2018 Jan 11
FDA Approves Isentress for Tx of HIV in Newborns, Merck news release; 2017 Nov 29
FDA Approves First 2-Drug Regimen for HIV, FDA news release; 2017 Nov 21
FDA Approves Two-Dose Hep B Vaccine , Dynavax news release; 2017 Nov 9